|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The management of cancer pain in the elderly显示文摘 | Urban D Chemy N Catane R | 2010 | Crit Rev Oncol Hematol2010，73，2： | 1 |
| 2 | Cancer-related paln:a pan-European survey of prevalence,treatment,and patient attitudes显示文摘 | Breivik H Chemy N Conett B etal | 2009 | Ann Oncol2009，20，8： | 1 |
| 3 | Evaluation and manmgement of treatment - related diarrhea in patients with advanced cancer: a review 显示文摘 | Chemy N I | 2008 | J Pain Symptom Manage2008，36，4： | 1 |
| 4 | Darstellung von organylborhalogeniden 显示文摘 | N OTH H VAHRENKAMP H Beitrage zur chemie des bors XLI | 1968 | J Organometallic Chem1968，11，： | 1 |
| 5 | Opioid pharmaco- therapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of an- algesic drugs and routes of administration显示文摘 | Chemy N J Chang V Frager G | 1995 | Cancer1995，76，： | 1 |
| 6 | Morphine and alternative opioids in cancer pain: the EAPC recommendations 显示文摘 | Hanks GW Conno F Chemy N | 2001 | Br J Cancer2001，84，5： | 1 |
| 7 | Cancer-related pain: a pan- European survey of prevalence, treatment, and patient attitudes显示文摘 | Breivik H Chemy N Collett B | 2009 | Ann Oncol2009，20，8： | 1 |
| 8 | Cancer-related pain: a pan-Euro-pean survey of prevalence, treatment, and patient attitudes 显示文摘 | Breivik H Chemy N Collett B | 2009 | Ann On-col2009，20，8： | 1 |
| 9 | Themanagement of cancer pain显示文摘 | Chemy N | 2000 | Cancer J Clin2000，50，： | 1 |
| 10 | Nonopioid and opioid analgesic pharmacotherapy of cancer pain显示文摘 | Chemy N I Foley K M | 1996 | Hematol Oncol Clin North Am1996，10，1： | 1 |
| 11 | Pain measurement tools and methods in clinical research in paliiative eare:rvcommendatiom of an expert working group of the european association of palliative care显示文摘 | Caraceni A Chemy N Fainsinger R | 2002 | J Pain Symptom Manage2002，23，3： | 1 |
| 12 | Morphine and alternative opioids in cancer pain:the EAPC recommendations显示文摘 | Hanks GW Conno F Chemy N | 2001 | Br J Cancer2001，84，5： | 1 |
| 13 | Tests of one-way osttensioned slabs with unbonded tendons 显示文摘 | Bums N H Vine W R Chemy F A | 1978 | PCI Journal1978，23，5： | 1 |
| 14 | A Th2-score in the tumor microenvironment as a predictive biomarker of response to Bacillus Calmette Guérin in patients with non-muscle invasive bladder carcinoma:A retrospective study显示文摘Intravesical Bacillus Calmette Guerin(BCG)is the gold standard therapy for intermediate/high-risk nonmuscle invasive bladder cancer(NMIBC).However,the response rate is~60%,and 50%of non-responders will progress to muscle-invasive disease.BCG induces massive local infiltration of inflammatory cells(Th1)and ultimately cytotoxic tumor elimination.We searched for predictive biomarker of BCG response by analyzing tumor-infiltrating lymphocyte(TIL)polarization in the tumor microenvironment(TME)in pre-treatment biopsies.Pre-treatment biopsies from patients with NMIBC who received adequate intravesical instillation of BCG(n=32)were evaluated retrospectively by immunohistochemistry.TME polarization was assessed by quantifying the T-Bet+(Th1)and GATA-3+(Th2)lymphocyte ratio(G/T),and the density and degranulation of EPX+eosinophils.In addition,PD-1/PD-L1 staining was quantified.The results correlated with BCG response.In most non-responders,Th1/Th2 markers were compared in pre-and post-BCG biopsies.ORR was 65.6%in the study population.BCG responders had a higher G/T ratio and a greater number of degranulated EPX+cells.Variables combined into a Th2-score showed a significant association with higher scores in responders(p=0.027).A Th2-score cut-off value>48.1 allowed discrimination of responders with 91%sensitivity but lower specificity.Relapse-free survival was significantly associated with the Th2-score(p=0.007).In post-BCG biopsies from recurring patients,TILs increased Th2-polarization,probably reflecting BCG failure to induce a pro-inflammatory status and,thus,a lack of response.PD-L1/PD-1 expression was not associated with the response to BCG.Our results support the hypothesis that a preexisting Th2-polarized TME predicts a better response to BCG,assuming a reversion to Th1 polarization and antitumor activity. | GUSTAVO MARTÍN VILLOLDO MARÍA TERESA POMBO MARIANA ARIS JOAQUÍN CHEMI PABLO MANDÓ SUPRIYA NAGARAJU JUAN CAMEAN ADRIÁN BURIONI DEBORAH EGEA MORA AMAT JOSÉLEÓN MELLADO JOSÉMORDOH ALBERTO VILLARONGA MARÍA MARCELA BARRIO | 2023 | Oncology Research2023，31，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员